Clinical Trial Update: Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update reports safety and tolerability findings for the investigational therapy IBI355 in patients with primary Sjogren's syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• IBI355

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Primary Sjögren's Syndrome | Phase 1 | Status: COMPLETED